A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

Anita Kumar, Kristie A. Blum, Henry C. Fung, Mitchell R. Smith, Paul A. Foster, Anas Younes

Research output: Contribution to journalLetterpeer-review

10 Scopus citations
Original languageEnglish
Pages (from-to)902-904
Number of pages3
JournalBritish Journal of Haematology
Volume168
Issue number6
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Keywords

  • Clinical trials
  • Hodgkin lymphoma
  • Immunotherapy
  • Monoclonal antibodies
  • Therapy

Fingerprint

Dive into the research topics of 'A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this